作者: Marina Parra-Robert , Aida Orois , Josep Maria Augé , Irene Halperin , Xavier Filella
关键词:
摘要: BACKGROUND Medullary thyroid carcinoma (MTC) is a neuroendocrine tumor caused by malignant transformation in the parafollicular C-cells of thyroid, where calcitonin (CT) released. Nowadays main markers (TM) used diagnosis and follow-up MTC patients are CT carcinoembryonic antigen (CEA). Nonetheless, progastrin releasing peptide (proGRP) has been recently proposed as TM useful MTC. Our aims were to investigate release proGRP tumors, its role assessment advanced utility differential between non-MTC tumors. METHODS Serum samples from 22 with 16 collected. Patients classified into cancer or no evidence disease (NED). ProGRP was performed Architect (Abbot Diagnostics), Liaison (Diasorin) CEA Cobas E601(Roche Diagnostics). RESULTS median concentration significantly higher (1398.4 pg/mL) when compared non-MTC, either (24.9 NED (14.6 pg/mL). In patients, below cutoff level (50 Similar CT, able detect 88.9% but slightly lower specificity 76.9%. Using together sensitivity increased 100%. CONCLUSIONS The low prevalence this malignancy strongly recommends further collaborative studies, mainly focused on monitoring during tyrosine kinase inhibitors treatment for early detection resistance assessing usefulness avoid observed false positive fluctuations that occur CEA.